The Wall Street Transcript has recently published its exclusive interview with Gerald R. Mattys, the CEO and Director of Tactile Systems Technology, Inc. (NASDAQ:TCMD).
“Mr. Mattys: Lymphedema is a pretty horrific condition that is progressive, so it gets worse if not treated, and today there is no cure. Lymphedema patients of all types, as in both lower-extremity and upper-extremity patients, as well as now in the head and neck as well can use the device. It is addressing a pretty under-penetrated and underappreciated market opportunity.
It is estimated that between 3 to 5 million patients in the U.S. have lymphedema. Many of them do not know what they have. Therefore, they are not necessarily seeking treatment for lymphedema. We have done some market research via reimbursement claims data over the last few years and identified that, in 2015, over 820,000 patients were diagnosed with lymphedema. So this 820,000 we look at as our directly addressable market opportunity, and that is what we are targeting. Those patients know they have a problem and are looking for help. In that year, we put about 16,000 systems on patients. So 16,000 on 820,000 speaks to what we think will be a continuing opportunity for us to address.”
For a free report and the other top investment highlights from the in depth interview with Gerald R. Mattys, the CEO and Director of Tactile Systems Technology, Inc. (NASDAQ:TCMD), visit TWST.com.
# # #
NOTE TO INVESTORS AND FINANCIAL NEWS EDITORS: Gerald R. Mattys, the CEO and Director of Tactile Systems Technology, Inc. (NASDAQ:TCMD) is available for interviews. Contact Tactile Systems at https://www.tactilemedical.com/about/.
– See more at https://www.twst.com/report/medical-devices-10/